Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma.

Key facts

Study ID

NCT00017264

Run by

National Cancer Institute (NCI)

Starts

2002-06-01

Last updated by the study team

2009-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Josephine Ford Cancer Center at Henry Ford Hospital — Detroit, Michigan, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• Abramson Cancer Center at University of Pennsylvania Medical Center — Philadelphia, Pennsylvania, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.